버리디안 테라퓨틱스(VRDN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $21.98 (+0.23%), 시가총액 $1.78B, 52주 최저~최고 $13.30 ~ $33.78.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comp
버리디안 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
버리디안 테라퓨틱스의 현재 주가는 $21.98 (+0.23%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
버리디안 테라퓨틱스의 시가총액은 약 $1.78B입니다.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including